Schering-Plough Animal Health Corporation Introduces New Neonatal Calf Diarrhea Vaccine

NEW JERSEY, US - Contemporary viruses and subunit E. coli are distinguishing features.
calendar icon 8 February 2005
clock icon 2 minute read

Schering-Plough Animal Health Corporation announced the introduction of Guardian®, a vaccine for maternal immunization to help protect newborn calves against neonatal calf diarrhea, or scours, caused by rotavirus, coronavirus, Escherichia coli, and Clostridium perfringens types B, C, and D. Scours is the leading cause of newborn calf mortality. "Guardian is unique because of its components," says Norman Stewart, DVM, MS, manager of Schering-Plough Animal Health technical services.

"It contains multiple strains of the most prevalent rotavirus and coronavirus for protection against contemporary viral causes of scours. It contains subunit E. coli for a specific and safe immune response with reduced likelihood of local or systemic reactions. And it contains two types of Cl. perfringens that together provide protection against three causes of enterotoxemia."

Stewart reports that the rotavirus, coronavirus, and E. coli components of Guardian were proven effective in challenge-of-immunity studies.

"In fact, in the E. coli challenge, mortality was reduced by 95% among calves from vaccinated dams," he says.

Vaccination with Guardian is a two-dose regimen. The product is available in 10- and 50-dose bottles. Schering-Plough Animal Health Corporation is a leading manufacturer and marketer of biologicals, pharmaceuticals, and specialty products for food and companion animals. It is the worldwide animal health business of Schering-Plough Corporation (NYSE:SGP) of Kenilworth, N.J., a research-based company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide.

For more information on Schering-Plough Animal Health, visit . News Desk

© 2000 - 2023 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.